Jason Sheltzer (Cold Spring Harbor Laboratory) discusses challenges and best practices to generating gene knockouts in cell lines using CRISPR-Cas9, as well as his group’s tour de force application of the technology to reveal stunning discrepancies between drugs that are in clinical trials and their supposed mechanism of action.
